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Abstract
Inflammation is an important biological process involved in many target organ toxicities. However, 
there has been little consensus on how to represent inflammatory processes using the adverse 
outcome pathway (AOP) framework. In particular, there were concerns that inflammation was not 
being represented in a way that it would be recognized as a highly connected, central node within 
the global AOP network. The consideration of salient features common to the inflammatory 
process across tissues was used as a basis to propose three hub key events for use in AOP network 
development. Each event, “tissue resident cell activation”, “increased pro-inflammatory 
mediators”, and “leukocyte recruitment/activation” is viewed as a hallmark of inflammation, 
independent of tissue, and can be independently measured. Using these proposed hub key events it 
was possible to link together a series of AOPs, that previously had no shared key events. 
Significant challenges remain with regard to accurate prediction of inflammation-related 
toxicological outcomes even if a broader and more connected network of inflammation-centered 
AOPs is developed. Nonetheless the current proposal addresses one of the major hurdles 
associated with representation of inflammation in AOPs and may aid fit-for-purpose evaluations of 
other AOPs operating in a network context.
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Introduction
Framing the Problem
The adverse outcome pathway (AOP) framework was developed to help organize existing 
knowledge concerning the linkage between stressor-induced perturbation of biological 
pathways and adverse outcomes considered relevant to risk assessment and regulation 
(Ankley et al. 2010). As such, AOPs are envisioned as an important component of a new 
toxicity testing paradigm that is expected to increasingly rely on mechanistic data, generally 
measured at low levels of biological organization using high throughput approaches, as a 
foundation for chemical safety assessment (Kleinstreuer et al. 2016). Likewise, AOPs are 
envisioned to have application in chemical category formation, design of integrated 
approaches to testing and assessment, and development of computational toxicity prediction 
models (Wittwehr et al. 2017; Edwards et al. 2016). An international AOP development 
program, coordinated through the Organization for Economic Cooperation and Development 
(OECD) and facilitated through description and dissemination of AOPs via an open access 
knowledgebase (aopwiki.org; aopkb.org) has emerged to support these efforts (Edwards et 
al. 2016; http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-
screening-and-toxicogenomics.htm).
The AOP framework, implemented via the AOP knowledgebase, employs a modular 
structure in which information is organized concerning measurements of biological state that 
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reflect progression from the initial perturbation toward the adverse outcome (key events, 
KEs), and scientific evidence supporting the linkage from one KE to the next in a causal and 
predictive sequence (key event relationships, KERs; Villeneuve et al. 2014a). This modular 
structure is employed so that descriptions of common elements (KEs or KERs) can be 
shared among multiple AOPs in order to increase the efficiency of development and to 
broaden the scope of their application by allowing for de facto construction of AOP 
networks from independently described AOPs. An AOP network is defined as a system of 
two or more AOPs that share one or more KEs (Knapen et al. 2017). Because it is expected 
that real-world exposures will often involve multiple AOPs, the ability to visualize and 
evaluate AOPs in a network context is important for many potential applications (Villeneuve 
et al. 2014a; Knapen et al. 2017). For example, one of the most obvious applications is in the 
assessment of mixtures where some chemicals may act on different MIEs that contribute 
jointly to common downstream effects while others may have opposing effects on KEs 
pertaining to the same biological object (i.e., agonism and antagonism of the same receptor).
Inflammation is a common response to a variety of stressors, including xenobiotics. Under 
normal conditions, inflammation is a healthy and adaptive process that both combats 
infection and is involved in repairing damage to tissues. However, xenobiotics can elicit 
prolonged, severe, and/or inappropriate inflammatory responses that play a causal role in the 
progression of biological events linking a molecular initiating event (MIE) to an adverse 
outcome (AO). This is reflected in the observation that inflammation has long been known to 
play a prominent role in human disease and a variety of target organ toxicities.
Given its prominent role in target organ toxicities, it was anticipated that inflammation 
would emerge as a highly connected node within an AOP network. However, as 
inflammation is a complex, multi-stage process, it was not clear what would serve as the 
appropriate level of abstraction for describing one or more KEs that capture the most salient, 
measurable hallmarks of inflammation, while also accommodating linkage to the wide range 
of upstream causes and downstream effects that are associated with the process. In 
particular, there was no consensus on whether inflammation should be represented as a 
single KE, and if so, how it would be measured, or whether it should be divided into a series 
of KEs. Likewise, it was unclear whether the inflammatory process was unique to every 
tissue or whether there were common features that could reasonably be generalized across 
tissues. Finally, if inflammation was divided into more than one event, it was unclear 
whether those events would occur in sequence (i.e., following the linear construction typical 
of most AOPs), or whether the events would be so concurrent and inextricably linked that 
they would need to be represented as parallel or interconnecting branches or through 
introduction of an “and” type logic gate (i.e., A and B must happen in order to cause C).
Approach and Objectives
In order to address on-going uncertainties about how to best represent inflammation using 
the AOP framework, experts with different backgrounds in research, toxicology, and 
medicine, specialized in immunology, immune toxicology, cancer research, inflammatory 
diseases of different organs (liver, lung, kidney, brain) and endocrine-immune interactions 
convened at the Joint Research Center (Ispra, Italy), on 27–28 of September, 2017 to discuss 
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this challenge and provide some recommendations on how inflammatory processes might be 
represented using the AOP framework. Discussions focused on a number of key topics and 
questions. First and foremost was an emphasis on the biology and identifying the most 
salient and indicative features of inflammation. Inflammatory processes in different target 
organs were discussed and compared to identify the extent to which the process generalizes 
across various tissues and organs and what aspects of the biology are context-specific. The 
common understanding of the biology was then used as a foundation for discussion of an 
appropriate level of resolution/abstraction with which to describe inflammation using the 
AOP framework. Furthermore, important aspects of the quantitative understanding of KERs 
that underlie the process were considered. This included discussion of whether there were 
measurements or indicators that distinguish appropriate, healthy, inflammatory responses 
from adverse inflammatory responses. Likewise, the need to identify important modulating 
factors that are known to either influence the severity of an inflammatory response or alter 
an organism’s susceptibility to develop an AO as a result of an inflammatory state (e.g., 
Roth et al., 2008; Maiuri et al., 2015) and therefore may need to be considered in 
inflammation-related KERs, was discussed.
The objective of the present manuscript is not to provide a comprehensive or critical review 
of the biology and toxicology of inflammation. Rather the aim is focused on representation 
of inflammatory processes using the AOP framework. Specifically, we sought to: (1) identify 
commonalities in the inflammatory process in different tissues and organs; (2) identify one 
or more KEs that could serve as common nodes in AOP networks; (3) agree on a consensus 
solution for integration of inflammation using the AOP framework; and (4) provide 
recommendations for how best to represent inflammation in the AOP framework and 
communicate these recommendations to relevant stakeholders (e.g., AOP developers; 
OECD; scientists studying inflammation). While it is expected that scientific uncertainty and 
debate over the specific details of inflammatory toxicology will continue, it is hoped that 
these recommendations provide a workable path forward for representation of this critical 
biology within the framework.
Salient Features of the Inflammatory Process
Regardless of the tissue, the inflammatory process can be organized into a number of 
sequential steps (Figure 1; Lawrence et al., 2002). Interaction of healthy tissues with a 
stressor can evoke the release of mediators that initiate inflammation. For example, direct 
damage to cells/tissues as a result of chemical reactivity leads to the release of molecular 
signals termed damage associated molecular pattern molecules [DAMPs], pathogen 
associated molecular pattern molecules (PAMPs, released by invading pathogens), or 
alarmins (Chan et al. 2012; Escamilla-Tilch et al. 2013; Schaefer 2014). These include a 
wide range of signal-initiating molecules that vary among cell types and include proteins, 
RNA or DNA, bacterially-derived lipopolysaccharides, small molecule metabolites (e.g., 
metabolic byproducts of bacteria, fungi, plants, etc.), and a variety of carbohydrates, which 
activate pattern recognition receptors, such as toll-like receptors and others. Certain 
xenobiotics may also mimic these molecular signals, without direct damage to cells. The 
tissue and stressor-specific combinations, concentrations, and durations of these signals is 
thought to “program” the ensuing inflammatory response.
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The diverse upstream signals involved in induction of inflammation subsequently activate 
resident cells of affected tissues (Davies et al. 2013; Wynn et al. 2013). Activation refers to a 
phenotypic modification of the resident cells that includes alterations in their secretions, 
activation of biosynthetic pathways, production of pro-inflammatory proteins and lipids, 
changes in the metabolism and sensing of small molecules, and morphological changes 
(Hussel and Bell, 2014). While these represent a pleiotropic range of responses that can vary 
with the tissue, there are a number of common markers or signs of activation that are 
measurable.
Activation of tissue resident cells promotes the release of pro-inflammatory mediators, 
including pro-inflammatory cytokines, chemokines, vasoactive amines, and lipid mediators. 
Release of these signals into the tissue, as well as the circulation, promotes the recruitment 
of bone-marrow derived leukocytes (e.g., neutrophils and monocytes) that differentiate into 
mature pro-inflammatory cells, in response to mediators they encounter in the local tissue 
microenvironment. If persistent and unchecked, the pro-inflammatory actions of recruited 
cells can promote tissue injury, for example through the release of reactive oxygen and 
nitrogen species, which often characterizes acute adverse responses to pro-inflammatory 
signaling.
Under normal circumstances, once a sufficient pro-inflammatory response has been 
mounted, pro-inflammatory mediators will be supplanted by the release of anti-
inflammatory mediators. These consist of a broad range of molecules that serve to both 
suppress immune response and promote resolution of inflammation and the repair of the 
damaged tissue. This phase is associated with differentiation of macrophages to an anti-
inflammatory wound repair phenotype (Hussel and Bell, 2014). In cases where damage is 
on-going (chronic), leading to repeated cycles of damage and repair, fibrosis and other repair 
associated lesions can form in the affected tissue. These can eventually progress to the point 
of tissue dysfunction, triggering various diseases (AO). Conditions such as immune 
suppression, angiogenesis, and cell proliferation associated with repair can create favorable 
conditions for cancer formation. However, in cases where the damage is relatively acute and 
adequately repaired, the tissue can return to a “normal” homeostatic state, characterized as a 
generally quiescent cellular milieu.
It is important to note that although the inflammatory process can be organized into this 
generalized sequence, there is overlap between these states. Some signals ramp up as others 
decline. The cells in the tissue change dynamically in terms of both numbers and phenotypes 
as the process progresses. Additionally, waves of subsequent damage due to flare-ups of a 
pathogen, chronic exposures to a chemical stressor, or introduction of another insult (i.e., a 
“second hit”) can restart the process, such that there are overlapping waves occurring 
throughout different microenvironments in the tissue and organs that are not necessarily in 
phase with each other.
This all lends to a picture of inflammation as a highly complex process with stochastic 
components. While many of the actors, their roles, and the stages they act upon (in terms of 
tissue-specific milieus) are known, existing knowledge is generally not adequate to predict 
the specific company of actors that will respond to any particular stressor, their sequence, or 
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the specific outcomes that will ensue. The signals and cell types responding to any given 
stressor/exposure scenario are defined largely by the type and context of the tissue. 
Additionally, the factors deemed most relevant are influenced by investigator opinion and 
what those individual investigators choose to measure (or don’t), which in turn shapes our 
current understanding of inflammation. While the same could be said for most fields of 
study, it is noted here in recognition of the daunting challenge we face in drawing 
quantitative or even semi-quantitative inference or predicting outcomes along inflammation-
mediated AOPs. Although various markers or hallmarks of inflammation can reasonably be 
viewed as red flags or indicators of potential or even probable hazard, their application as 
reliable quantitative predictors of outcome is likely to be limited. With this caveat, we 
considered how inflammatory response can be represented and described using the AOP 
framework.
Hub Key Events for Inflammation-related AOP Networks
Through consideration of the salient features of the inflammatory process, three generalized 
KEs (tissue resident cell activation; increased pro-inflammatory mediators; leukocyte 
recruitment/activation) were proposed as candidates for common nodes (hubs) that could be 
shared by a diversity of AOPs involving inflammation (Figure 2). Each KE corresponds with 
one of the generalized sequential steps involved in inflammatory response in a tissue (gray 
shaded in Figure 1). Each of these broad processes was viewed as a generalizable hallmark 
of inflammation, independent of the tissue. Although they are closely linked, each can be 
measured independent of one another. Together, they are viewed as a minimum set of 
common denominators reflective in the inflammatory process across tissues.
Each of these events is consistent with the definition of a KE as reflecting a measureable 
change in biological state that is demonstrably essential to progression along the pathway, 
but not necessarily sufficient by itself to cause adversity (i.e., just because these events are 
observed, does not mean injury will occur – only that it could, based on current scientific 
understanding and evidence; Villeneuve et al. 2014a). However, these proposed hub KEs run 
counter to some of the conventions and best practices concerning KE description (Villeneuve 
et al. 2014b). Most notably, the title of the events does not clearly indicate what biological 
object (e.g., protein, metabolite, cell type, etc.) should be measured. This is because while 
the function/biological role/toxicodynamics of the event is well conserved across different 
tissues and organisms, the specific “actors” that are playing these roles, and thus how the 
measurements are made can vary. For example, in liver measures of “tissue resident cell 
activation” may focus on Kupffer cells, while in the brain they might focus on microglia or 
in bone osteoclasts (Davies et al. 2013). In terms of the ontological description of KE 
components (Ives et al. 2017), these KEs are viewed as well conserved in their “process” 
and “action” terms. However, the specific “object” terms can be expected to vary with tissue, 
environment and context and will need to be described for different tissue contexts as each 
KE description is expanded/revised for use with different AOPs (e.g., Table 1).
The three proposed hub KEs were viewed as reflecting functional points of convergence in 
relation to a diverse array of upstream, stressor-specific signals. Likewise, they were 
functional points of divergence in relation to different tissue- and context-specific outcomes. 
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Thus, they could be viewed as the “knot” in classic bow tie structures in systems biology 
(Friedlander et al. 2015) and thus are well suited to serve as central, highly connected, nodes 
within an AOP network (Knapen et al. 2017).
Pilot Implementation
Following the proposal of the hub KEs, corresponding event pages were created in the AOP-
Wiki (https://aopwiki.org/events/1492; https://aopwiki.org/events/1493; https://aopwiki.org/
events/1494). As a pilot, these events were integrated into a number of existing AOPs 
(Figure 3) linking different MIEs to distinct inflammation-mediated AOs or to AOPs where 
inflammation is an essential exacerbating element (https://aopwiki.org/; AOP 13; 38; 173; 
one novel AOP not yet in the AOP-Wiki). By introducing these hub KEs, it is now possible 
to link together AOPs that were previously disconnected (Figure 4) in the overall AOP 
network represented in the AOP-Wiki. The previously defined AOPs were readily adapted to 
incorporate the proposed hub KEs. For example, for AOP 38 (Figure 3C) Kupffer cell 
(resident macrophages) activation aligned with “tissue resident cell activation” and TGF-β1 
expression corresponded with “Increased pro-inflammatory mediators”. The third hub KE 
“Leukocyte recruitment/ activation” had not been displayed as a separate KE in the original 
version of AOP 38, because that process had been incorporated into the description of the 
Kupffer cell activation KE. Likewise, in the case of an AOP leading to neurotoxicity (AOP 
13; Figure 3B) it was possible to link neuroinflammation – which is considered a 
neurospecific process relying on specific neural cells - with the postulated hub KEs and their 
generic description. This allowed interconnectivity with other AOPs unrelated to the brain 
(Figure 4).
Next steps and Perspectives
Through deliberations on the biology and toxicology of inflammation, a consensus proposal 
was achieved with regard to an appropriate level of abstraction with which to represent the 
process of inflammation within a broad AOP network. The proposed level of abstraction 
resolves inflammation into three hallmark KEs that are expected to be functionally 
equivalent across multiple AOPs. However, the specific objects or actors involved in these 
functions are expected to vary by AOP according to the tissue specific context. This solves 
the primary challenge of representing inflammation in a way that is biologically appropriate 
yet is generalizable enough to facilitate AOP network connectivity, which was our major 
aim.
The approach recommended here is somewhat of a departure from current conventions 
regarding the description of KEs (Villeneuve et al. 2014b). While the biological function/
process each KE represents is well conserved across different tissue contexts, the specific 
objects (e.g., genes, proteins, metabolites) one would measure as appropriate indicators of 
these KEs are likely to be tissue-dependent. This will require creativity, careful thought, and 
perhaps some trial and error, in terms of how best to structure the KE descriptions for these 
events. Likewise, with experience, guidance regarding the minimum set of tissue-specific 
object changes that represent “triggering” of a given KE may need to be defined. 
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Nonetheless, it should facilitate our ability to represent inflammation in an AOP network 
context.
We and others (Leist et al. 2017) have noted the potential predictive limitations of 
inflammation-related AOPs based on the fact that they are inherently dependent on the 
relative balance of damage and repair and the associated timing and conditions of exposure. 
The proposed hub KEs do not specifically address that potential limitation to the predictive 
utility of the AOP framework in such circumstances. However, accepting this limitation, the 
ability to better represent inflammation in an AOP network is still highly beneficial. 
Specifically, it may help to more effectively differentiate those AOPs involving or 
intersecting with an inflammatory component, where more sophisticated models or in vivo 
testing may be required to predict outcomes, from those acting independent of inflammation 
where predictive confidence may be higher. In this way, the ability to identify intersection 
with inflammatory KE hubs aids the evaluation of fit-for-purpose of specific AOPs and AOP 
networks for different types of decision-making. Consequently, consensus around how to 
best represent inflammation via a set of hub KEs represents a significant step forward in the 
evolution and application of the AOP framework.
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Figure 1. 
Generalized model of sequential steps involved in inflammatory response in a tissue. 
Sequence of chevrons indicates anticipated adaptive/protective response to a damage signal. 
Arrows indicate trajectory diverging from an adaptive homeostatic state to a maladaptive/
adverse response. DAMPs = damage associated molecular patterns; PAMPs = pathogen 
associated molecular patterns; BM = bone marrow.
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Figure 2. 
Overview of three key events (KEs, blue boxes) associated with hallmarks of inflammation 
that were proposed for use as potential hub KEs in inflammation-related adverse outcome 
pathway (AOP) networks. The three events are viewed as points of convergence between a 
wide range of potential stressor-dependent upstream signals that can induce inflammatory 
response and points of divergence toward a wide range tissue and context-dependent adverse 
outcomes. One or all of these KEs may be included in a given AOP, and in some cases the 
order, particularly of the first two, may be reversed, consequently no arrows between the 
blue boxes are shown. Note “Tissue Resident Cell Activation” may also include activation of 
resident/patrolling leukocytes.
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Figure 3. 
Four adverse outcome pathways (AOPs) shown before (above the horizontal dashed line) 
and after (below the horizontal dashed line) incorporation of the proposed hub key events 
(blue shaded). A. A network of two AOPs linking induction and secretion of inflammatory 
cytokines to lung fibrosis (AOP 173; https://aopwiki.org/aops/173) or lung emphysema 
(novel AOP not yet entered in the AOP-Wiki). Revised titles, resident cell activation leading 
to lung fibrosis or lung emphysema, respectively. B. AOP linking chronic binding of 
antagonists to N-methyl-D-aspartate receptors (NMDARs) during brain development to 
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neurodegeneration with impairment of learning and memory in aging (AOP 13; https://
aopwiki.org/aops/13). C. AOP linking protein alkylation to liver fibrosis (AOP 38; https://
aopwiki.org/aops/38).
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Figure 4. 
Network composed of four adverse outcome pathways (AOPs; https://aopwiki.org/aops; 
AOPs 13, 38, 173 and one novel AOP not yet in the AOP-Wiki) illustrating how 
incorporation of the proposed hub key events facilitates improved connectivity of disparate 
inflammation-related AOPs within a broader AOP network.
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Table 1.
Illustration of process/object/action terms (see Ives et al. 2017) that would define the proposed “hub” key 
event titled “increased pro-inflammatory mediators”. Note, the object listing is intended to be illustrative, not 
comprehensive.
Key Event Title
Event Components
Process Object Action
Increased pro-inflammatory mediators Inflammation TNF-alpha Increase
IL-1
IL-6
CXCL2
CCL2
Histamine
Prostaglandins
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